Xcout Intel
Triveni Bio
Triveni Bio is a clinical-stage biotechnology company that utilizes human genetics and advanced antibody engineering to develop first-in-class therapeutics for immune and inflammatory diseases. The company's pipeline includes bispecific antibody candidates, such as TRIV-573, designed to address conditions like atopic dermatitis by targeting specific biological pathways.
Subscribe to see Triveni Bio’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Triveni Bio at a glance
Triveni Bio is a biotech company. Xcout tracks 22 named people at Triveni Bio, including Ram Aiyar (Chief Executive Officer and President, Korro Bio). Xcout recorded 6 job postings from Triveni Bio in the last 90 days.
Triveni Bio leadership
- Ram AiyarChief Executive Officer and President, Korro Bio
- Vishal PatelChief Executive Officer
- Akshay VaishnawFormer President, Alnylam Pharmaceuticals
- Nicholas ScarchilliChief Operating Officer
- Will ChenChief Technology Officer at Passkey Therapeutics
- Allison LuoChief Medical Officer, Prometheus Biosciences
16 more named people on record for Triveni Bio, with roles, board committees and tenure — see the full roster →
Hiring at Triveni Bio
Xcout recorded 6 job postings from Triveni Bio in the last 90 days, from a hiring record Xcout has kept since September 2026.
The weekly hiring trend, the roles and locations behind it — see Triveni Bio's hiring signals →
Tech stack
Triveni Bio competitors
A few of Triveni Bio's closest competitors — see the full list of competitors and alternatives →
Modify Therapeutics was a biotechnology company that focused on the development of antibody therapeutics targeting hard-to-treat inflammatory diseases, with a specific focus on gastrointestinal disorders. The company merged with Amagma Therapeutics to form Triveni Bio.
A clinical-stage biopharmaceutical company developing biotherapeutics for immune-mediated diseases using its ATTOBODY biologics platform. The company's lead candidate, ATTO-1310, targets interleukin-31 (IL-31), known as the 'itch cytokine,' for the treatment of chronic pruritic diseases including atopic dermatitis. Its pipeline also includes multi-specific candidates for other inflammatory diseases.
Villaris Therapeutics was a clinical-stage biotechnology company developing antibody-based therapies for autoimmune and inflammatory skin diseases. Its intended beneficiaries were patients with immune-mediated dermatologic conditions.
Trellis Bioscience, Inc. is a clinical-stage biotechnology company located in Redwood City, California, focused on developing antibody-based therapeutics.
Tr1X is a private, clinical-stage biotechnology company focused on developing regulatory T cell-based products for autoimmune and inflammatory diseases. The company aims to advance Tr1-based immunotherapies to address unmet medical needs and is headquartered in San Diego, California.
ImageneBio Inc (IMA) is a biotechnology company with therapies currently undergoing human trials. The firm concentrates on creating innovative medical treatments for a variety of immune-related and inflammatory diseases. A key component of their pipeline is IMG-007, a non-depleting anti-OX40 monoclonal antibody, which is now in Phase 2b clinical studies targeting atopic dermatitis.
Get Triveni Bio's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about Triveni Bio? Suggest a correction
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Triveni Bio in Xcout Intel
- 22 named people with titles, LinkedIn and board committees
- Weekly hiring history and the mix of roles behind it
- The full competitor set, tracking, exports and API access